| Yuan, Xianglin |
| Recruiting | 4 | 40 | RoW | Hetrombopag Olamine | Huazhong University of Science and Technology | Malignant Tumors of the Digestive System, Trombocitopenia | 10/23 | 12/23 | | |
NCT03236649: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects |
|
|
| Terminated | 3 | 89 | RoW | Icaritin, Sorafenib Tosylate Tablets | Beijing Shenogen Biomedical Co., Ltd, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Eastern Theater General Hospital,QinHuai District Medical Area, Peking University Cancer Hospital & Institute, Chinese PLA General Hospital, Beijing Hospital, General Hospital of Chinese Armed Police Forces, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, The Fourth Hospital of Hebei Medical University, Hunan Cancer Hospital, The First Hospital of Jilin University, 307 Hospital of PLA, Fudan University, Henan Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital of Soochow University, Tongji Hospital, Beijing YouAn Hospital | Hepatocellular Carcinoma (HCC) | 02/22 | 02/22 | | |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
GAPSO, NCT03801668: Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma |
|
|
| Recruiting | 3 | 294 | RoW | Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1 | Huazhong University of Science and Technology, CSPC Ouyi Pharmaceutical Co., Ltd. | Gastric Cancer | 12/22 | 03/23 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
NCT05918094: Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 3 | 540 | RoW | Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab | Sun Yat-sen University | Gastric Cancer | 12/26 | 12/28 | | |
NCT05687357: Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma |
|
|
| Recruiting | 2b | 140 | RoW | Tislelizumab, S-1, Oxaliplatin, Nab paclitaxel, Radiation | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Gastric Cancer, Gastroesophageal-junction Cancer | 02/27 | 08/27 | | |
NCT04603040: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers |
|
|
| Recruiting | 2 | 100 | RoW | Toripalimab, Tuoyi | Shanghai Junshi Bioscience Co., Ltd. | Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy | 12/22 | 03/23 | | |
NCT05438108: SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC |
|
|
| Recruiting | 2 | 30 | RoW | SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab | Huazhong University of Science and Technology | Metastatic Colorectal Cancer | 01/23 | 01/24 | | |
NCT04294784: Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer |
|
|
| Terminated | 2 | 58 | RoW | Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor), Albumin-bound Paclitaxel | Huazhong University of Science and Technology | Gastric Cancer, GastroEsophageal Cancer | 11/23 | 11/23 | | |
NCT06168786: Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC |
|
|
| Recruiting | 2 | 40 | RoW | Fruquintinib, Cadonilimab, SBRT | Huazhong University of Science and Technology | Colorectal Cancer | 02/26 | 02/27 | | |
NCT06516445: SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC |
|
|
| Recruiting | 2 | 33 | RoW | SCRT, Camrelizumab, Fluzoparib, CAPEOX | Huazhong University of Science and Technology | Colorectal Cancer | 06/25 | 06/26 | | |
NCT06199895: Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer |
|
|
| Recruiting | 2 | 25 | RoW | Paclitaxel Polymeric Micelles for Injection | Liu Huang | Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Stomach Cancer, Esophageal Carcinoma, Breast Cancer | 11/25 | 11/25 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study |
|
|
| Recruiting | 2 | 276 | RoW | LM302+Toripalimab, LM302+JS001 | LaNova Medicines Zhejiang Co., Ltd. | Gastric Cancer, Pancreatic Cancer | 07/25 | 01/26 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT06592287: The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer |
|
|
| Not yet recruiting | 1/2 | 66 | RoW | Adebrelimab + Apatinib + Lrinotecan liposome | Xianglin Yuan | Advanced Gastric Cancer | 09/25 | 09/26 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
NCT02490319: Study on the Biological Prediction Models of Radiation Pneumonitis |
|
|
| Recruiting | N/A | 300 | RoW | | Huazhong University of Science and Technology | Radiation Pneumonitis | 07/23 | | | |
NCT06551207: Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC |
|
|
| Recruiting | N/A | 80 | RoW | Fruquintinib, Cadonilimab, SBRT | Liu Huang | Metastatic Colorectal Cancer | 12/26 | 12/27 | | |
NCT05448703: A Study on Predictive Models and Clinical Outcome of Radiation Pneumonitis |
|
|
| Recruiting | N/A | 300 | RoW | Blood Samples for Biomarkers | Huazhong University of Science and Technology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jingjiang People' Hospital | Radiation Pneumonitis | 09/26 | 09/26 | | |
| Shu, Chang |
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD |
|
|
| Recruiting | 3 | 388 | RoW | HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis | Shanghai Henlius Biotech | Age Related Macular Degeneration | 08/23 | 03/24 | | |
NCT04275323: Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1) |
|
|
| Completed | 3 | 302 | RoW | NL003, HGF plasmid, pCK-HGF-X7, Normal Saline, Placebo | Beijing Northland Biotech. Co., Ltd. | Arterial Occlusive Disease, Ischemia, Ulcers, Peripheral Vascular Disease | 06/24 | 06/24 | | |
| Completed | 3 | 242 | RoW | NL003, HGF plasmid, pCK-HGF-X7, Normal Saline, Placebo | Beijing Northland Biotech. Co., Ltd. | Arterial Occlusive Disease, Ischemia, Ulcers, Peripheral Vascular Disease | 12/23 | 12/23 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT06000956: A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo |
|
|
| Recruiting | 3 | 408 | RoW | Jitongning tablets, a simulated agent of Jitongning tablets | Tasly Pharmaceutical Group Co., Ltd | Ankylosing Spondylitis | 12/26 | 12/26 | | |
| Recruiting | 2 | 62 | RoW | ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w | Abbisko Therapeutics Co, Ltd | Hepatocellular Carcinoma | 07/24 | 10/24 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
PATENCY, NCT03767777: Prospective Study for Aortic Arch Therapy With stENt-graft for Chimney technologY（） |
|
|
| Enrolling by invitation | N/A | 150 | RoW | Artery Stent Graft System | Lifetech Scientific (Shenzhen) Co., Ltd. | Thoracic Aortic Dissection | 06/21 | 12/25 | | |
NCT06725212: Evaluation of the Water Vapor Thermal Therapy System for the Treatment of Benign Prostatic Hyperplasia |
|
|
| Recruiting | N/A | 126 | RoW | Water Vapor Thermal Ablation, Water Vapor Ablation, Cystoscopy | Medtecx Co Ltd. | Benign Prostatic Hyperplasia | 06/25 | 06/26 | | |
NCT05126446: the Aorta Arch Stent Graft System Combined With the Endovascular Needle System in Situ Fenestration |
|
|
| Active, not recruiting | N/A | 120 | RoW | the Aorta Arch Stent Graft System combined with the Endovascular Needle System | Lifetech Scientific (Shenzhen) Co., Ltd. | Aortic Dissection | 10/27 | 03/28 | | |
NCT06520774: Concave Supra-arch Branched Stent-Graft System for Endovascular Treatment of Aortic Arch Diseases |
|
|
| Not yet recruiting | N/A | 103 | NA | Concave Supra-arch Branched Stent-Graft System | Lifetech Scientific (Shenzhen) Co., Ltd., Second Xiangya Hospital of Central South University | Aortic Arch Aneurysm, Penetrating Aortic Ulcer | 10/27 | 10/31 | | |
NCT04765605: Guo's Subclavian Artery Reconstruction: The Prospective, Multiple Center Study of WeFlow-Tbranch Stent Graft System(GUEST Study) |
|
|
| Active, not recruiting | N/A | 120 | RoW | WeFlow-Tbranch Stent Graft System | Hangzhou Endonom Medtech Co., Ltd. | Type B Aortic Dissection | 12/26 | 12/26 | | |
